×

Affimed Announces Fourth Quarter and Year End 2015 Financial Results and Corporate Update Conference Call

HEIDELBERG, Germany, March 23, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD) today announced that on March 30, 2016, the Company will release its financial results for the quarter and year ended December 31, 2015. The Company's management team will host a conference call to discuss the Company's financial results and recent corporate developments on Wednesday, March 30, 2016 at 8:30 a.m. EST. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 5864817.

Local - Amsterdam, the Netherlands: +31 (0) 20 716 8295
Local - Copenhagen, Denmark: +4532 71 1660
Local – Frankfurt, Germany: +49 (0) 69 2222 10628
Local - Geneva, Switzerland: +41 (0) 22 592 79 53
Local - London, U.K.: +44 (0) 20 3427 1906
Local - New York City, U.S.A.: +1 212 444 0412
Local - Paris, France: +33 (0) 1 76 77 22 29

An audio webcast of the conference call can be accessed in the "Events" section on the "Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available on Affimed's website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.

About Affimed N.V.

Affimed (Nasdaq:AFMD) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed's product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed's proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit www.affimed.com.

IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: IR@affimed.com or c.stewart@affimed.com

Media Contact:
Anca Alexandru, Head of Communications
Phone: +49 6221 64793341
E-Mail: a.alexandru@affimed.com

Source:Affimed Therapeutics